EIF4E and breast cancer: Similarly, tamoxifen-resistant ER+ BC cells also exhibited elevated mTORC1 activity, concomitant with high levels of total and phosphorylated eIF4E; suppression of mTORC1/MNK1 activity using everolimus/CGP57380, or reducing eIF4E levels via si/shRNA, resensitized cells to tamoxifen [152].